Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: The GERCOR NEONIPIGA phase II Study - André, T; Tougeron, D; Piessen, G (J Clin Oncol, 2022)
et al.